Cargando…

Preclinical Evaluation of the Acute Radiotoxicity of the α-Emitting Molecular-Targeted Therapeutic Agent (211)At-MABG for the Treatment of Malignant Pheochromocytoma in Normal Mice

The α-emitter (211)At-labeled meta-astatobenzylguanidine ((211)At-MABG) has a strong antitumor effect on pheochromocytoma xenograft tumors and holds great promise as a new therapeutic option for malignant pheochromocytoma. To evaluate the acute radiation-related toxicity of (211)At-MABG, we conducte...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sudo, Hitomi, Tsuji, Atsushi B., Sugyo, Aya, Nagatsu, Kotaro, Minegishi, Katsuyuki, Ishioka, Noriko S., Ito, Hiroshi, Yoshinaga, Keiichiro, Higashi, Tatsuya
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Neoplasia Press 2019
Materias:	Original article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6514325/ https://www.ncbi.nlm.nih.gov/pubmed/31078058 http://dx.doi.org/10.1016/j.tranon.2019.04.008

Ejemplares similares

Antitumor effects of radionuclide treatment using α-emitting meta-(211)At-astato-benzylguanidine in a PC12 pheochromocytoma model
por: Ohshima, Yasuhiro, et al.
Publicado: (2018)

OR03-01 Effects Of Alpha-emitting Meta-(211)At-astato-benzylguanidine ((211)At-MABG) Compared To (131)I-meta-iodobenzylguanidine ((131)I-MIBG) on Tumor Growth Suppression in a Pheochromocytoma Mouse Model
por: Yoshinaga, Keiichiro, et al.
Publicado: (2020)

In Vitro Evaluation of No-Carrier-Added Radiolabeled Cisplatin ([(189, 191)Pt]cisplatin) Emitting Auger Electrons
por: Obata, Honoka, et al.
Publicado: (2021)

Preclinical Development of [(211)At]meta- astatobenzylguanidine ([(211)At]MABG) as an Alpha Particle Radiopharmaceutical Therapy for Neuroblastoma
por: Batra, Vandana, et al.
Publicado: (2022)

Precise quantitative evaluation of pharmacokinetics of cisplatin using a radio-platinum tracer in tumor-bearing mice
por: Obata, Honoka, et al.
Publicado: (2022)

α‐particle therapy for synovial sarcoma in the mouse using an astatine‐211‐labeled antibody against frizzled homolog 10
por: Li, Huizi Keiko, et al.
Publicado: (2018)

Human dosimetry of free (211)At and meta-[(211)At]astatobenzylguanidine ((211)At-MABG) estimated using preclinical biodistribution from normal mice
por: Ukon, Naoyuki, et al.
Publicado: (2020)

Preclinical Evaluation of Podoplanin-Targeted Alpha-Radioimmunotherapy with the Novel Antibody NZ-16 for Malignant Mesothelioma
por: Sudo, Hitomi, et al.
Publicado: (2021)

Novel Auger-Electron-Emitting (191)Pt-Labeled Pyrrole–Imidazole Polyamide Targeting MYCN Increases Cytotoxicity and Cytosolic dsDNA Granules in MYCN-Amplified Neuroblastoma
por: Obata, Honoka, et al.
Publicado: (2023)

Manual on the proper use of meta-[(211)At] astato-benzylguanidine ([(211)At] MABG) injections in clinical trials for targeted alpha therapy (1st edition)
por: Ukon, Naoyuki, et al.
Publicado: (2022)

Anti-tumor effects and potential therapeutic response biomarkers in α-emitting meta-(211)At-astato-benzylguanidine therapy for malignant pheochromocytoma explored by RNA-sequencing
por: Ohshima, Yasuhiro, et al.
Publicado: (2019)

Evaluation of (89)Zr-Labeled Human Anti-CD147 Monoclonal Antibody as a Positron Emission Tomography Probe in a Mouse Model of Pancreatic Cancer
por: Sugyo, Aya, et al.
Publicado: (2013)

Proof of Concept Study for Increasing Tenascin-C-Targeted Drug Delivery to Tumors Previously Subjected to Therapy: X-Irradiation Increases Tumor Uptake
por: Sugyo, Aya, et al.
Publicado: (2020)

Therapeutic efficacy evaluation of radioimmunotherapy with (90)Y‐labeled anti‐podoplanin antibody NZ‐12 for mesothelioma
por: Sudo, Hitomi, et al.
Publicado: (2019)

Development of Novel (191)Pt-Labeled Hoechst33258: (191)Pt Is More Suitable than (111)In for Targeting DNA
por: Obata, Honoka, et al.
Publicado: (2022)

FZD10‐targeted α‐radioimmunotherapy with (225)Ac‐labeled OTSA101 achieves complete remission in a synovial sarcoma model
por: Sudo, Hitomi, et al.
Publicado: (2021)

Efficacy Evaluation of Combination Treatment Using Gemcitabine and Radioimmunotherapy with (90)Y-Labeled Fully Human Anti-CD147 Monoclonal Antibody 059-053 in a BxPC-3 Xenograft Mouse Model of Refractory Pancreatic Cancer
por: Sugyo, Aya, et al.
Publicado: (2018)

Radiolabeled Human Monoclonal Antibody 067-213 has the Potential for Noninvasive Quantification of CD73 Expression
por: Sudo, Hitomi, et al.
Publicado: (2020)

The natural sulfoglycolipid derivative SQAP improves the therapeutic efficacy of tissue factor-targeted radioimmunotherapy in the stroma-rich pancreatic cancer model BxPC-3
por: Takakusagi, Yoichi, et al.
Publicado: (2021)

Uniform intratumoral distribution of radioactivity produced using two different radioagents, (64)Cu-cyclam-RAFT-c(-RGDfK-)(4) and (64)Cu-ATSM, improves therapeutic efficacy in a small animal tumor model
por: Jin, Zhao-Hui, et al.
Publicado: (2018)

Promising Gene Therapeutics for Salivary Gland Radiotoxicity
por: Nair, Renjith Parameswaran, et al.
Publicado: (2016)

Combined treatment of pancreatic cancer xenograft with (90)Y-ITGA6B4-mediated radioimmunotherapy and PI3K/mTOR inhibitor
por: Aung, Winn, et al.
Publicado: (2017)

In vivo validation of the switch antibody concept: SPECT/CT imaging of the anti-CD137 switch antibody Sta-MB shows high uptake in tumors but low uptake in normal organs in human CD137 knock-in mice
por: Sugyo, Aya, et al.
Publicado: (2022)

The radiotoxic and conventional toxic relevance of Hg-target inventories
por: R. Moormann, K. Bongardt, H. Brücher, B. Lensing, H. Schaal
Publicado: (02/1)

A (211)At-labelled mGluR1 inhibitor induces cancer senescence to elicit long-lasting anti-tumor efficacy
por: Xie, Lin, et al.
Publicado: (2023)

(111)In-labeled anti-cadherin17 antibody D2101 has potential as a noninvasive imaging probe for diagnosing gastric cancer and lymph-node metastasis
por: Fujiwara, Kentaro, et al.
Publicado: (2019)

SAT-211 Is Doxazosin the Right Choice for Preoperative Management of Pheochromocytoma in Pregnancy?
por: Bustos, Mario, et al.
Publicado: (2020)

Therapeutic Efficacy of C-Kit-Targeted Radioimmunotherapy Using 90Y-Labeled Anti-C-Kit Antibodies in a Mouse Model of Small Cell Lung Cancer
por: Yoshida, Chisato, et al.
Publicado: (2013)

Immunotargeting of Integrin α(6)β(4) for Single-Photon Emission Computed Tomography and Near-Infrared Fluorescence Imaging in a Pancreatic Cancer Model
por: Aung, Winn, et al.
Publicado: (2016)

Gallium-67 radiotoxicity in human U937 lymphoma cells.
por: Jonkhoff, A. R., et al.
Publicado: (1993)

Synthesis of no-carrier-added [(188, 189, 191)Pt]cisplatin from a cyclotron produced (188, 189, 191)PtCl(4)(2−) complex
por: Obata, Honoka, et al.
Publicado: (2021)

Cyclotron production of (225)Ac from an electroplated (226)Ra target
por: Nagatsu, Kotaro, et al.
Publicado: (2021)

Evaluation of Efficacy of Radioimmunotherapy with (90)Y-Labeled Fully Human Anti-Transferrin Receptor Monoclonal Antibody in Pancreatic Cancer Mouse Models
por: Sugyo, Aya, et al.
Publicado: (2015)

Radioimmunotherapy of pancreatic cancer xenografts in nude mice using (90)Y-labeled anti-α(6)β(4) integrin antibody
por: Aung, Winn, et al.
Publicado: (2016)

A comparison of the chemo- and radiotoxicity of thorium and uranium at different enrichment grades
por: Rump, A., et al.
Publicado: (2023)

Hydrogen-rich water attenuates the radiotoxicity induced by tritium exposure in vitro and in vivo
por: Li, Hong, et al.
Publicado: (2020)

α‐Emitting cancer therapy using (211)At‐AAMT targeting LAT1
por: Kaneda‐Nakashima, Kazuko, et al.
Publicado: (2021)

Protection from contamination by (211)At, an enigmatic but promising alpha-particle-emitting radionuclide
por: Ohnuki, Kazunobu, et al.
Publicado: (2022)

Immuno-OpenPET: a novel approach for early diagnosis and image-guided surgery for small resectable pancreatic cancer
por: Yoshii, Yukie, et al.
Publicado: (2020)

Quantitative Radionuclide Imaging Analysis of Enhanced Drug Delivery Induced by Photoimmunotherapy
por: Aung, Winn, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_9fi7k6fu59ho424ksgkqjcfb7k